Formulation comprising a gemcitabine-prodrug
AssigneeNuCana plc
InventorsHugh Griffith, Gordon Kennovin
Life of this patent
Estimating the term…
Abstract
This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations which comprise a polar aprotic solvent, preferably dimethyl acetamide (DMA). Formulations comprising these solvent provide therapeutically effective treatments of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. The invention also relates to methods of using said formulations and kits comprising said formulations.
Claims12
1-25. (canceled)
A pharmaceutical formulation comprising:
- from 10% to 60% by volume DMA;
- from 10% to 80% by volume solubilizer or solubilizers;
- from 1% to 15% by volume aqueous vehicle;
- and
- from 50 mg to 150 mg per mL gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate,
- wherein each solubilizer is a non-ionic surfactant or a mixture thereof;
- and
- wherein the aqueous vehicle is selected from saline, glucose solution and water for infusion (WFI).
A method of treating cancer, the method comprising:
- diluting a solution comprising:
- from 10% to 60% by volume DMA;
- from 30% to 80% by volume solubilizer or solubilizers;
- from 1% to 15% by volume aqueous vehicle;
- and
- from 50 mg to 150 mg per mL gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate, with an aqueous vehicle to provide a formulation for infusion or injection;
- and
- administering the formulation for infusion or injection to the subject by infusion or injection,
- wherein each solubilizer is a non-ionic surfactant or a mixture thereof;
- and
- wherein the aqueous vehicle is selected from saline, glucose solution and water for infusion (WFI).
Dependencies are inferred from the claim text.